PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93839

Toshikazu USHIJIMA, et al.

Appln. No.: 10/572,352

Group Art Unit: 1634

Confirmation No.: 1137

Examiner: Ethan C. Whisenant

Filed: November 2, 2006

For: METHOD FOR ACCESSING CANCEROUS STATE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

- 1. Sato N., et al. "Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays," Cancer Research, Vol. 63, No. 13, pages 3735-3742 (July 1, 2003).
- 2. Hagihara A., et al. "Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers," Oncogene, Vol. 23, No. 53, pages 8705-8710 (November 11, 2004).
- 3. WO 03/076594 A to The Johns Hopkins University published September 18, 2003.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Appln. No.: 10/572,352

Attorney Docket No.: Q93839

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications

filed after June 30, 2003.

The present Information Disclosure Statement is being filed (without a Statement Under

37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the

mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of

Allowance, or an action that otherwise closes prosecution in the application (whichever is

earlier), and therefore the fee of \$180.00 under 37 C.F.R. § 1.17(p) is being remitted.

Applicant encloses herewith a copy of a corresponding Supplementary European Search

Report citing such documents and indicating the degree of relevance found by the foreign patent

office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 51,822

Joseph Hsiao

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 14, 2009

2